<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/64F5B912-92CD-489B-A071-6CA22EFAAAA9"><gtr:id>64F5B912-92CD-489B-A071-6CA22EFAAAA9</gtr:id><gtr:name>Weizmann Institute of Science</gtr:name><gtr:address><gtr:line1>PO Box 26</gtr:line1><gtr:line2>Rehovot 76100</gtr:line2><gtr:line4>Rehovot</gtr:line4><gtr:postCode>76100</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64F5B912-92CD-489B-A071-6CA22EFAAAA9"><gtr:id>64F5B912-92CD-489B-A071-6CA22EFAAAA9</gtr:id><gtr:name>Weizmann Institute of Science</gtr:name><gtr:address><gtr:line1>PO Box 26</gtr:line1><gtr:line2>Rehovot 76100</gtr:line2><gtr:line4>Rehovot</gtr:line4><gtr:postCode>76100</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4F6D5C16-9376-4E97-BEA0-72DE59AB77C9"><gtr:id>4F6D5C16-9376-4E97-BEA0-72DE59AB77C9</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Wills</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8BEDD4C5-BE70-4AE0-A4E2-F9F913C5FFC7"><gtr:id>8BEDD4C5-BE70-4AE0-A4E2-F9F913C5FFC7</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Jackson</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3380185E-6DE2-4756-8D0B-5075DF9636BC"><gtr:id>3380185E-6DE2-4756-8D0B-5075DF9636BC</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:surname>Poole</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BBD65048-AED3-4824-ACD7-DEA6923DA9C3"><gtr:id>BBD65048-AED3-4824-ACD7-DEA6923DA9C3</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Sinclair</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK021087%2F1"><gtr:id>B3C015A0-A7BC-472C-B737-50633CC280BC</gtr:id><gtr:title>Human cytomegalovirus: changes in the latently infected cell as chemotherapeutic and immunological targets for antiviral therapy</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K021087/1</gtr:grantReference><gtr:abstractText>Human cytomegalovirus (HCMV) is a type of herpesvirus which is carried without symptoms by the majority of the population. However, it can cause serious disease in infants born to mothers who acquire the infection in pregnancy and in people whose immune systems are suppressed, for instance when they undergo transplantation for an organ such as a kidney or bone marrow it can be life threatening. The fact that up to 3 people are dying a day because of a lack of a suitable transplant organs and this is resulting in a call for increases in the number of transplants in the UK (http://www.bbc.co.uk/news/health-11688102), HCMV disease is likely to become more and more of a problem in transplant patients.
Unlike many other viruses, HCMV is never cleared after its initial infection but persists for the life time of the individual. At least in part, this is due to the ability of HCMV to avoid the immune system by expression of virus genes which help it avoid immune responses. However, the lifelong persistence of this virus is also a biological property of all herpesviruses because the virus is able to undergo a so-called latent infection, where the virus hides in the cell without making new virus particles but is still able to reawaken, generating new infectious virtues which can cause disease and can also be passed on to other uninfected people. 
Understanding how the virus succeeds in maintaining itself in most people without causing disease and how this relationship breaks down to cause disease should help develop better methods of treating the virus and for designing a vaccine (there is currently no vaccine available).
Our research is aimed at determining (i) the mechanism by which the virus maintains a silent infection (latency) in specialised cells of the immune system and how these help the virus reawaken (reactivation) and (ii) how the immune system is prevented from eliminating the virus from the body.
In addition to advancing our understanding of HCMV, in particular, this research may also lead to a better understanding of other virus infections which persist in the body, how the human host controls and help identify common strategies for their elimination.</gtr:abstractText><gtr:technicalSummary>Human cytomegalovirus (HCMV) primary infection of the immunocompetent is asymptomatic. However, infection of individuals with compromised or immature immune systems can be life threatening. Furthermore, HCMV persists for the lifetime of the host which, at least in part, is due to the ability of HCMV to avoid immunesurveillance and, ultimately,establish a latent infection. Cellular latency is defined as genome carriage with viral transcription limited to a few latency-associated genes and no infectious virus production. Consequently, current therapies targeting HCMV replication will not target the latent virus. However, viral reactivation from latency is a major cause of disease in immune suppressed transplant patients. Furthermore, there is increasing evidence associating HCMV with long-term diseases (i.e. atherosclerosis, chronic graft rejection and neoplasias) with reactivation of latent HCMV likely to be a major source of virus. Consequently, therapeutics that target latently infected cells could have far reaching clinical implications. 
Work from our laboratory has been instrumental in identifying a subset of viral genes expressed during HCMV latency, the host immune responses to these latency-associated antigens,and how these genes modify the latently infected cell.In the case of expression of viral UL138 during latency, we have already identified changes in the latently infected cell mediated by UL138 expression allowing them to be targeted chemotherapeutically. 
We propose to build on this work and comprehensively analyse the effects of expression of additional viral latency-associated genes on the cell and the immune response. Such analyses will allow a more comprehensive understanding of how this human pathogen persists for the lifetime of the host and also identify additional changes in the latently infected cell which can be further exploited for chemotherapeutic and immunological targets to lead to credible strategies aimed at eliminating latent virus.</gtr:technicalSummary><gtr:potentialImpactText>Human cytomegalovirus (HCMV) is universally distributed in human populations and, like herpesviruses, persists throughout life following primary infection. HCMV remains an important human pathogen, particularly in the settings of congenital infection; it is the commonest infective cause of congenital central nervous system damage and a major cause of morbidity and mortality in immunocompromised subjects (Rubin Rev Infect Dis 1990. Drew Rev Infect Dis 1988), especially in the context of organ and bone marrow allografting. Whilst antiviral therapy is available, significant side effects and drug resistance occur. Additionally, treatment does not eliminate the virus which can subsequently reactivate and cause further morbidity. Consequently, HCMV headed the list of vaccines needed by the US in the report from the Institute of Medicine on Priorities for Vaccines (Arvin Clin Infect Dis 2004), in part reflecting the weighting this gave to quality life years saved. 
Understanding virus pathogenesis at a molecular level during both lytic infection and latency, and thus how viral gene products interact with host immune responses, is crucial for rational design of therapeutics - both novel antiviral strategies and approaches to vaccines. For HCMV, this is increasingly important; not least because of the calls for transplant organs by the BMA and Government (http://www.bbc.co.uk/news/health-11688102) but also because there is increasing opinion that long-term persistence of HCMV, which encompasses reactivation from latency, is associated with long-term diseases such as atherosclerosis, chronic graft rejection and neoplasias.
This research will directly benefit research academics (UK and international) both in the herpesvirus community as well as communities interested in the mechanisms of immunity and immune evasion; providing immediate impact for the duration of the grant.
Similarly, the National Institute of Health Research (NIHR) community clearly benefits from any successful outcomes of the proposed research programme through decreased transplantation-mediated HCMV disease.The University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, as one of the 11 NIHR Comprehensive Biomedical Research Centres (BRC) in the UK, are ideally placed to adopt new insights in technologies, techniques and treatments for improving health and to translate fundamental biomedical research into clinical research that benefits patients: Infection &amp;amp; Immunity is one of the 11 themes in our BRC, which will help facilitate the translational research associated with this application.
We expect our research to inform industrial partners interested in vaccine and drug development as results from the proposed research will provide key information both for vaccine design and for drug targeting. For instance, a successful vaccine program of women prior to pregnancy will have very clear health impacts through the prevention of congenital infections and the subsequent long term health care costs associated with treating these patients.
Our proposed programme will support two technicians and two postdoctoral scientists, all of whom are supported by our present programme of work. Our long-term funding has allowed, and will continue to allow, our research technicians to become highly skilled laboratory workers. Their in-house training will also enable them to move into higher level managerial and teaching roles vital for the effective running of research groups and University Departments. The training that our post-doctoral researchers receive, not only in laboratory based research but also in undergraduate and PhD student teaching as well as oral and written presentational skills, will enable them to move on to academic posts to develop their own research programs as well as to become well trained scientists who would also be highly valued by industry.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1597081</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Microbiology &amp; Infectious Diseases</gtr:department><gtr:description>T cell control of lytic HCMV infection</gtr:description><gtr:id>5C758B34-C4BF-4A5C-B07D-233719BA62F8</gtr:id><gtr:impact>Publication:-

Leukocyte Immunoglobulin-Like Receptor 1-Expressing Human Natural Killer Cell Subsets Differentially Recognize Isolates of Human Cytomegalovirus through the Viral Major Histocompatibility Complex Class I Homolog UL18.
Chen KC, Stanton RJ, Banat JJ, Wills MR.
J Virol. 2016 Jan 6;90(6):3123-37. doi: 10.1128/JVI.02614-15.</gtr:impact><gtr:outcomeId>56d99265415870.17113255-1</gtr:outcomeId><gtr:partnerContribution>Dr Stanton has been generating viral mutants removing key immune evasion genes of interest to be used in our anti-viral assay.</gtr:partnerContribution><gtr:piContribution>We have generated a anti-viral assay system which can be used to investigate the immunological control of lytic replicating cytomegalovirus and allow us to understand the function of viral immune evasion genes and which cellular components of immune response are resonsible for virustatic and virucidal action</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Are latency antigen specific regulatory T cells generated during the primary immune response?</gtr:description><gtr:id>6090D928-A05A-4F10-B354-1C8AEAC341D4</gtr:id><gtr:impact>none as yet only just started</gtr:impact><gtr:outcomeId>5460de88983234.10628982-1</gtr:outcomeId><gtr:partnerContribution>PBMC from patients receiving HCMV seropositive kidney transplants from the earliest time available post seroconversion will be provided alongside relevant clinical data.</gtr:partnerContribution><gtr:piContribution>CD4+ and CD8+ T cells and assayed in IFN? and cIL-10 ELISPOT assays following stimulation with LUNA, US28, UL111A, UL138 and UL144 peptides. PBMC are available up to several years post seroconversion and will be tested as outlined above. This analysis will allow us to determine when latency specific CD4+ T cells are generated and if regulator cIL10 producing cells are rapidly generated in the primary immune response or develop later. We will also be able to address if CD8+ T cells are generated to these antigens and potentially lost from the memory pool.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection and Population Health</gtr:department><gtr:description>Analysis of LUNA</gtr:description><gtr:id>064EC5A8-30C3-4E34-A97D-F43BE8FA5151</gtr:id><gtr:impact>Reeves et al 2010. Human cytomegalovirus IE72 protein interacts with the transcriptional repressor hDaxx to regulate LUNA gene expression during lytic infection J. Virol 84:7185</gtr:impact><gtr:outcomeId>Ydz95qU4TtY-1</gtr:outcomeId><gtr:partnerContribution>co-analysers of the LUNA gene product</gtr:partnerContribution><gtr:piContribution>Analysis of the control of the HCMV latency-associated LUNA gene product of HCMV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cleveland Clinic Foundation</gtr:department><gtr:description>Analysis of latency-associated transcripts</gtr:description><gtr:id>54F38E23-57A1-44CA-9ACA-59A08F54127A</gtr:id><gtr:impact>Betty Lau, Emma Poole, Ellen Van Damme, Lieve Bunkens, Madeleine Sowash, Harry King, Eain Murphy, Mark Wills, Marnix Van Loock, John Sinclair 2016. Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early gene expression during latency to prevent T cell recognition of latently infected cells Published ahead of print 10.1099/jgv.0.000546
 Betty Lau, Emma Poole, Benjamin Krishna, Immaculada Sellart, Mark R. Wills, Eain Murphy, and&amp;not; John Sinclair (2016) The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6. Sci Rep. 6 :31205, doi:10.1038/srep31205</gtr:impact><gtr:outcomeId>77868117C59-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators helped us to define latent transcripts further work on which was funded by an MRC Programme Grant renewal</gtr:partnerContribution><gtr:piContribution>Our research led to the detection of certain viral genes during latent infection</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>US28 as a therapeutic target of latent HCMV infection</gtr:description><gtr:id>16C195BD-F670-4C42-AA04-5E7707B1E291</gtr:id><gtr:impact>Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein; Nature Communications NCOMMS-16-15473C, 2017, B. A. Krishna, K. Spiess, E. L. Poole, B. Lau, S. Voigt, T. N. Kledal, M. M. Rosenkilde, J. H. Sinclair</gtr:impact><gtr:outcomeId>544e08028337f2.47353199-1</gtr:outcomeId><gtr:partnerContribution>Provisions of reagents</gtr:partnerContribution><gtr:piContribution>We are providing the latent model for analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>proteomics analyses of latency-associated HCMV genes</gtr:description><gtr:id>3D754C21-CD4C-4C02-87B5-0C229EB94D5B</gtr:id><gtr:impact>Weekes, M.P, Tan SY, Poole E, Talbot S, Antrobus R, Smith DL, Montag C, Gygi SP, Sinclair JH, Lehner PJ. (2013) Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 340, 199-202.
Karniely S, Weekes MP, Antrobus R, Rorbach J, van Haute L, Umrania Y, Smith DL, Stanton RJ, Minczuk M, Lehner PJ, Sinclair JH. 2016. Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries. MBio 7</gtr:impact><gtr:outcomeId>h1ppmiHwVJ3-1</gtr:outcomeId><gtr:partnerContribution>Proteomic analysis to identify interaction partners with latency-associated HCMV genes</gtr:partnerContribution><gtr:piContribution>Analysis of the role of US28 and UL138-interacting proteins in HCMV latency</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Weizmann Institute of Science</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>Single Cell RNAseq of latently infected cells</gtr:description><gtr:id>72D9D6E4-98DF-4547-BE2C-5B5AB6797461</gtr:id><gtr:impact>None, yet</gtr:impact><gtr:outcomeId>58be7dd73e1207.38363014-1</gtr:outcomeId><gtr:partnerContribution>RNA sequencing of latently infected cells</gtr:partnerContribution><gtr:piContribution>We provide sorted latently infected CD34 and CD14 positive cells for RNAseq</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Infection Immunity and Inflammation PhD Programme</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>520AB09B-176F-46A5-B927-B8068AF3BE1C</gtr:id><gtr:outcomeId>58be7c3161f6f3.87468296</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS/DPFS</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS)</gtr:fundingOrg><gtr:fundingRef>P42942 RG69425</gtr:fundingRef><gtr:id>30408018-0614-493A-85DB-3A34B482F5FB</gtr:id><gtr:outcomeId>56d98bc6a6db49.29475921</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Collaborative award</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CA692193-62B7-4CDA-8779-68C8D64497BF</gtr:id><gtr:outcomeId>58b577b74de7c0.19049118</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Training Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AE48B39D-3DB6-466A-AA9D-DCB2B5C82F0E</gtr:id><gtr:outcomeId>tJq9rPvuBKS</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTP Doctoral Training Award</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:fundingRef>RG86932</gtr:fundingRef><gtr:id>9EC13466-0C0E-4F08-ACBF-C7A951CB4DE1</gtr:id><gtr:outcomeId>58aefd41598d01.30879237</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Doctoral Training Grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C6044932-B294-4C88-8074-8AE37999F27E</gtr:id><gtr:outcomeId>5460d5cf8859d3.16610688</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K021087/1</gtr:fundingRef><gtr:id>2D8CFA6C-EC5D-470E-97A9-4F4A02A8571B</gtr:id><gtr:outcomeId>FB3dqjpVP5N</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>430000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Glaxo Smith Kline Varsity Award</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>349FABCA-BE55-4E05-A046-CBA192FA48C9</gtr:id><gtr:outcomeId>58aefe272dde56.63814000</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR BRC pump priming Award</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D07729CC-385C-40CC-8982-5FE221EA2705</gtr:id><gtr:outcomeId>56d954237bd870.72615377</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>DETECTION AND DEPLETION OF HCMV INFECTED CELLS</gtr:description><gtr:grantRef>MR/K021087/1</gtr:grantRef><gtr:id>BE5EE9BF-0649-4E82-B662-21DE4AA36B68</gtr:id><gtr:impact>This is a proof of principle that latent HCMC infection could be targeted therapeutically</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>544e0aa7e63231.21895016</gtr:outcomeId><gtr:patentId>WO/2012/156733</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>DETECTION AND DEPLETION OF HCMV INFECTED CELLS</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>755AABF2-B73B-47D7-82A5-16763AD8CE7B</gtr:id><gtr:title>CMV immune evasion and manipulation of the immune system with aging.</gtr:title><gtr:parentPublicationTitle>GeroScience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b5466875d526da0c1bf7e2cb63a0d5"><gtr:id>14b5466875d526da0c1bf7e2cb63a0d5</gtr:id><gtr:otherNames>Jackson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2509-2723</gtr:issn><gtr:outcomeId>5a616c41d091d7.69569411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>162552D7-27F7-4204-9CFD-E1560CD99A90</gtr:id><gtr:title>Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9be5d4bd876990c9249237225a00a86"><gtr:id>b9be5d4bd876990c9249237225a00a86</gtr:id><gtr:otherNames>Krishna BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58aef915247e01.54247067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0057564C-AB98-44C5-AAE5-40DFCDE582A9</gtr:id><gtr:title>Human cytomegalovirus manipulation of latently infected cells.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0b3db78c0d3f2b49bc012cf14cf4a65"><gtr:id>a0b3db78c0d3f2b49bc012cf14cf4a65</gtr:id><gtr:otherNames>Sinclair JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>544e02a59459c4.38068596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A714AB71-5FA1-4EC1-9FEF-3CCCB613B4DF</gtr:id><gtr:title>Defining the Transcriptional Landscape during Cytomegalovirus Latency with Single-Cell RNA Sequencing.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e6bb90c3ecd2313b04b31efc9f94345"><gtr:id>6e6bb90c3ecd2313b04b31efc9f94345</gtr:id><gtr:otherNames>Shnayder M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa7b203e8e904.39467633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FF735EC-A7D1-4919-B254-A5234779DC01</gtr:id><gtr:title>Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early-gene expression during latency to prevent T-cell recognition of latently infected cells.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daee70c5606342c96f8f58ec103fb590"><gtr:id>daee70c5606342c96f8f58ec103fb590</gtr:id><gtr:otherNames>Lau B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58aef91480b8d4.90490936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40753C24-FEF0-417A-BCAB-AABE32D58893</gtr:id><gtr:title>Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04c8cc419a2f3be17568a098587458a0"><gtr:id>04c8cc419a2f3be17568a098587458a0</gtr:id><gtr:otherNames>Reeves M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_12893_23_23736881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF6C902C-DD50-44C8-BC05-BC9FBA9390CF</gtr:id><gtr:title>Latency-Associated Expression of Human Cytomegalovirus US28 Attenuates Cell Signaling Pathways To Maintain Latent Infection.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9be5d4bd876990c9249237225a00a86"><gtr:id>b9be5d4bd876990c9249237225a00a86</gtr:id><gtr:otherNames>Krishna BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a616efd51eb73.23060830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>627D59E5-5612-4BA4-A5C1-A45E0FDBA185</gtr:id><gtr:title>Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4? T cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_12893_23_24130479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53FEDD38-42FA-47AB-8B1E-B9721FEED786</gtr:id><gtr:title>Human Cytomegalovirus (HCMV)-Specific CD4T Cells Are Polyfunctional and Can Respond to HCMV-Infected Dendritic Cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b5466875d526da0c1bf7e2cb63a0d5"><gtr:id>14b5466875d526da0c1bf7e2cb63a0d5</gtr:id><gtr:otherNames>Jackson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>588b22398e5507.44964845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9E011FB-4D15-426D-9282-7312675FCE02</gtr:id><gtr:title>The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daee70c5606342c96f8f58ec103fb590"><gtr:id>daee70c5606342c96f8f58ec103fb590</gtr:id><gtr:otherNames>Lau B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58aef914bdf111.08446104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6675EB1-15A4-4FEE-9462-5F18A2F3B9B2</gtr:id><gtr:title>Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30a579c480a7d39ba6cfbec316a94a4e"><gtr:id>30a579c480a7d39ba6cfbec316a94a4e</gtr:id><gtr:otherNames>Van Damme E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>544e01b21242c4.88559887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73FF16CB-84F3-4557-A32A-F47AED0C5755</gtr:id><gtr:title>Human cytomegalovirus gene UL76 induces IL-8 expression through activation of the DNA damage response.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76685e447641d3db3472055633f2342d"><gtr:id>76685e447641d3db3472055633f2342d</gtr:id><gtr:otherNames>Costa H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_12893_23_24068928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C41FC6CB-D8DE-47EF-A158-7DABCF3632F1</gtr:id><gtr:title>How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/987969a32b3867694431eeeac23dc547"><gtr:id>987969a32b3867694431eeeac23dc547</gtr:id><gtr:otherNames>Sissons JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>56d94e46612bf4.05110488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA3D9539-736F-4238-8BD0-56CA0C562AE9</gtr:id><gtr:title>Sleepless latency of human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>5675e0dc4b804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AB4CBDE-EF2C-45EF-B0DF-718BAD5284C9</gtr:id><gtr:title>Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4100ef9fb20698f4ec92831656d998f9"><gtr:id>4100ef9fb20698f4ec92831656d998f9</gtr:id><gtr:otherNames>Avdic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d45fa2eadd30.39842427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9AF403D-5251-4FE4-9D1E-828E774EE9E6</gtr:id><gtr:title>Leukocyte Immunoglobulin-Like Receptor 1-Expressing Human Natural Killer Cell Subsets Differentially Recognize Isolates of Human Cytomegalovirus through the Viral Major Histocompatibility Complex Class I Homolog UL18.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23378a6af2fb1c8bb76b6c4f141d1d5a"><gtr:id>23378a6af2fb1c8bb76b6c4f141d1d5a</gtr:id><gtr:otherNames>Chen KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d94e463c3fe2.00269463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A089B071-43A1-4571-B0A9-A2D661A3CA88</gtr:id><gtr:title>Neurodevelopmental protein Musashi-1 interacts with the Zika genome and promotes viral replication.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1270492d2ea480007167cb12786c3713"><gtr:id>1270492d2ea480007167cb12786c3713</gtr:id><gtr:otherNames>Chavali PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5a6171155c9dd2.01488039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BBAE00A-DD0C-47C4-BB1E-A4B30466F65C</gtr:id><gtr:title>The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?</gtr:title><gtr:parentPublicationTitle>Cellular &amp; molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ac20894142731f9b0efe1c795b481ba"><gtr:id>1ac20894142731f9b0efe1c795b481ba</gtr:id><gtr:otherNames>Wills MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1672-7681</gtr:issn><gtr:outcomeId>doi_55f955955001dd72</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CF13AC1-781C-4553-88B5-675AA9C712FB</gtr:id><gtr:title>The use of primary human cells (fibroblasts, monocytes, and others) to assess human cytomegalovirus function.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-1-62703-787-7</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>544e0274560fb7.39413442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCB5784E-9870-4DA1-BA51-FC128612482C</gtr:id><gtr:title>Human Cytomegalovirus Latency: Targeting Differences in the Latently Infected Cell with a View to Clearing Latent Infection</gtr:title><gtr:parentPublicationTitle>New Journal of Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a2fd1f70ba061.06742535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6AD92C3-7DF7-4745-89F7-EAD96C141CA7</gtr:id><gtr:title>Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9be5d4bd876990c9249237225a00a86"><gtr:id>b9be5d4bd876990c9249237225a00a86</gtr:id><gtr:otherNames>Krishna BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58aef914ee0b45.87458392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86198C8F-6300-4E6B-8EA0-75ABE1C199C0</gtr:id><gtr:title>The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_23_23365437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C639A35E-42BE-4FCE-9C0D-7CE52EFAB0E3</gtr:id><gtr:title>Latency-associated viral interleukin-10 (IL-10) encoded by human cytomegalovirus modulates cellular IL-10 and CCL8 Secretion during latent infection through changes in the cellular microRNA hsa-miR-92a.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>544e01e14dd4e3.37928256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77F1417A-C909-4A8F-8B84-6D47433F4A24</gtr:id><gtr:title>Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b895d6f1022449850bff9b154540eb7"><gtr:id>6b895d6f1022449850bff9b154540eb7</gtr:id><gtr:otherNames>Weekes MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_12893_23_23580527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5AD9DEF-1B1B-40A2-B42C-BFD5BF273060</gtr:id><gtr:title>Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1fa95512c8c24498210be8597cb0d8"><gtr:id>6f1fa95512c8c24498210be8597cb0d8</gtr:id><gtr:otherNames>Reeves MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_23_23885077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB990996-225E-4260-9B9D-32ABCD01E0DB</gtr:id><gtr:title>Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b5466875d526da0c1bf7e2cb63a0d5"><gtr:id>14b5466875d526da0c1bf7e2cb63a0d5</gtr:id><gtr:otherNames>Jackson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5460c48a1c6c35.14175190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF74C199-4653-4528-A094-0FB09CE73BB0</gtr:id><gtr:title>The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease--Translational research with no translation.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>585d5885d5e154.41103433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F692C9-0827-4F3D-A205-6407CD903792</gtr:id><gtr:title>Latent infection of myeloid progenitors by human cytomegalovirus protects cells from FAS-mediated apoptosis through the cellular IL-10/PEA-15 pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56d45f600b3060.23804763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>931795E2-44C1-42BB-BB9D-C40D69B466C3</gtr:id><gtr:title>Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5082ca3a750c101b570e47dc3f91234"><gtr:id>c5082ca3a750c101b570e47dc3f91234</gtr:id><gtr:otherNames>Ingolia NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_55f954954ff50e0c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>762A1B8D-201B-4D42-BF9E-A0A30A707833</gtr:id><gtr:title>Alveolar Macrophages Isolated Directly From Human Cytomegalovirus (HCMV)-Seropositive Individuals Are Sites of HCMV Reactivation In Vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56d4600e13ad70.85422261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D5186E7-7444-4FC5-BBBD-9B82011269E1</gtr:id><gtr:title>The intimate relationship between human cytomegalovirus and the dendritic cell lineage.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880c79b4b226cab99274f0fae7128192"><gtr:id>880c79b4b226cab99274f0fae7128192</gtr:id><gtr:otherNames>Sinclair J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>544e021fb9a002.75629576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95AE9629-C50A-42B6-B013-59B48BEEF7CA</gtr:id><gtr:title>Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b5466875d526da0c1bf7e2cb63a0d5"><gtr:id>14b5466875d526da0c1bf7e2cb63a0d5</gtr:id><gtr:otherNames>Jackson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a3602c27cec71.16881006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>217B99AF-3516-42A2-9F55-086EFA1B1F55</gtr:id><gtr:title>Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d724df103e65732990a9b3434a133c1d"><gtr:id>d724df103e65732990a9b3434a133c1d</gtr:id><gtr:otherNames>Karniely S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d516196bb47.73294813</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K021087/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>